Update on pharmacotherapy for pulmonary hypertension
- PMID: 27627939
- DOI: 10.5694/mja16.00468
Update on pharmacotherapy for pulmonary hypertension
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis if not treated. Pharmacological treatment options for PAH have increased significantly over the past 10 years, with availability of intravenous, oral and inhaled drugs targeting the nitric oxide, endothelin and prostacyclin pathways. Treatment with these therapies in specialised pulmonary hypertension centres has resulted in reductions in patient symptoms, disease progression and mortality, and improved exercise capacity. Recognition of chronic thromboembolic pulmonary hypertension is important, as this cause of pulmonary hypertension may be amenable to surgical treatment. Several new oral drugs, including macitentan, riociguat and selexipag, some of which have novel modes of action, and the use of combinations of PAH drugs have recently been shown to be beneficial in treating PAH and are likely to change treatment for this condition in the future.
Similar articles
-
Pathways in pulmonary arterial hypertension: the future is here.Eur Respir Rev. 2012 Dec 1;21(126):321-7. doi: 10.1183/09059180.00004812. Eur Respir Rev. 2012. PMID: 23204120 Free PMC article. Review.
-
A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.Curr Pharm Des. 2017;23(34):5191-5199. doi: 10.2174/1381612823666170908114227. Curr Pharm Des. 2017. PMID: 28891448 Review.
-
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.Ann Am Thorac Soc. 2015 Feb;12(2):269-73. doi: 10.1513/AnnalsATS.201501-020AS. Ann Am Thorac Soc. 2015. PMID: 25590376
-
Selexipag for the treatment of pulmonary arterial hypertension.Expert Rev Respir Med. 2016;10(1):1-3. doi: 10.1586/17476348.2016.1121103. Epub 2015 Dec 7. Expert Rev Respir Med. 2016. PMID: 26567613
-
Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995048. doi: 10.1177/1753466621995048. Ther Adv Respir Dis. 2021. PMID: 33627044 Free PMC article.
Cited by
-
Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.ACS Pharmacol Transl Sci. 2020 Jul 1;3(4):598-612. doi: 10.1021/acsptsci.0c00048. eCollection 2020 Aug 14. ACS Pharmacol Transl Sci. 2020. PMID: 32832865 Free PMC article. Review.
-
The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension.Front Physiol. 2018 Aug 23;9:1167. doi: 10.3389/fphys.2018.01167. eCollection 2018. Front Physiol. 2018. PMID: 30190678 Free PMC article. Review.
-
Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.Int J Mol Sci. 2020 Jul 8;21(14):4827. doi: 10.3390/ijms21144827. Int J Mol Sci. 2020. PMID: 32650586 Free PMC article. Review.
-
Pulmonary Arterial Hypertension and Therapeutic Interventions.Int J Angiol. 2019 Jun;28(2):80-92. doi: 10.1055/s-0039-1692452. Epub 2019 Jun 28. Int J Angiol. 2019. PMID: 31384105 Free PMC article.
-
Pulmonary Arterial Hypertension: Pathophysiology and Treatment.Diseases. 2018 May 16;6(2):38. doi: 10.3390/diseases6020038. Diseases. 2018. PMID: 29772649 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous